To address these challenges, ElastiGate was evaluated on 40 samples stained with a 14-color T-cell panel designed to characterize the CD4+ and CD8+ immune repertoire of tumor-bearing mice after immunotherapy, including naive/effector/memory states and regulatory T cells. Here, CD8A is linked to neoplasm.